KR20250051643A - 항-slc34a2 단클론성 항체 및 그것의 용도 - Google Patents

항-slc34a2 단클론성 항체 및 그것의 용도 Download PDF

Info

Publication number
KR20250051643A
KR20250051643A KR1020257001435A KR20257001435A KR20250051643A KR 20250051643 A KR20250051643 A KR 20250051643A KR 1020257001435 A KR1020257001435 A KR 1020257001435A KR 20257001435 A KR20257001435 A KR 20257001435A KR 20250051643 A KR20250051643 A KR 20250051643A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257001435A
Other languages
English (en)
Korean (ko)
Inventor
룬솅 리
웬타오 황
이판 리
Original Assignee
라노바 메디신즈 디벨롭먼트 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라노바 메디신즈 디벨롭먼트 컴퍼니 리미티드 filed Critical 라노바 메디신즈 디벨롭먼트 컴퍼니 리미티드
Publication of KR20250051643A publication Critical patent/KR20250051643A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020257001435A 2022-06-22 2023-06-21 항-slc34a2 단클론성 항체 및 그것의 용도 Pending KR20250051643A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/100315 2022-06-22
CN2022100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20250051643A true KR20250051643A (ko) 2025-04-17

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257001435A Pending KR20250051643A (ko) 2022-06-22 2023-06-21 항-slc34a2 단클론성 항체 및 그것의 용도

Country Status (13)

Country Link
US (2) US12215150B2 (https=)
EP (1) EP4543926A1 (https=)
JP (1) JP2025520692A (https=)
KR (1) KR20250051643A (https=)
CN (1) CN119948054A (https=)
AU (1) AU2023289743A1 (https=)
CA (1) CA3260354A1 (https=)
CL (1) CL2024004012A1 (https=)
CO (1) CO2024017740A2 (https=)
IL (1) IL317849A (https=)
MX (1) MX2025000053A (https=)
TW (1) TW202409076A (https=)
WO (1) WO2023246879A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025131025A1 (en) * 2023-12-21 2025-06-26 Lanova Medicines Development Co., Ltd. Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603474B2 (en) 2008-01-29 2013-12-10 Ludwig Institute For Cancer Research, Ltd. Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US12215150B2 (en) 2025-02-04
EP4543926A1 (en) 2025-04-30
TW202409076A (zh) 2024-03-01
US20240301052A1 (en) 2024-09-12
AU2023289743A1 (en) 2025-01-09
CL2024004012A1 (es) 2025-05-02
JP2025520692A (ja) 2025-07-03
CO2024017740A2 (es) 2025-05-19
US20250154248A1 (en) 2025-05-15
MX2025000053A (es) 2025-04-02
CA3260354A1 (en) 2023-12-28
WO2023246879A1 (en) 2023-12-28
CN119948054A (zh) 2025-05-06
IL317849A (en) 2025-02-01

Similar Documents

Publication Publication Date Title
US12570742B2 (en) Anti-SIRPα monoclonal antibodies and uses thereof
AU2022201736B2 (en) Anti-GPRC5D monoclonal antibodies and uses thereof
US20250154248A1 (en) Anti-slc34a2 monoclonal antibodies and uses thereof
JP2023547530A (ja) 抗ｔｉｇｉｔ抗体およびその使用
WO2022148370A1 (en) Anti-gprc5d monoclonal antibodies and uses thereof
WO2023155796A1 (en) Anti-il-13ra2 monoclonal antibodies and uses thereof
TWI883306B (zh) 抗ｇｐｒｃ５ｄ單株抗體及其用途
WO2025131027A1 (en) Anti-slc34a2/anti-4-1bb antibodies and uses thereof
HK40126806A (zh) 抗slc34a2单克隆抗体及其用途
OA21935A (en) ‘‘Anti-IL-13RA2 Monoclonal Antibodies And Uses Thereof’’
HK40080157A (en) Anti-gprc5d monoclonal antibodies and uses thereof
HK40098542A (zh) 抗SIRPα单克隆抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application